Questions a plan sponsor actually asks.
What is Amphetamine Extended-Release used for?
Amphetamine Extended-Release treats ADHD and narcolepsy by increasing dopamine and norepinephrine activity.
Is there a generic for Amphetamine Extended-Release?
No. Amphetamine Extended-Release is brand-only with no generic equivalents currently in market.
How much does my plan pay for Amphetamine Extended-Release?
Across 329 Part D plans, Amphetamine Extended-Release averages $16.47/unit (NADAC). Lowest available: $16.31/unit. Highest in distribution: $16.58/unit.
Is Amphetamine Extended-Release on the FDA shortage list?
No. Amphetamine Extended-Release is not currently on the FDA Drug Shortage Database.
3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.